Author | Study design & population | Intervention | Expected Outcome |
---|---|---|---|
Trials of HSV-2 suppressive therapy | |||
Celum et al., 2008 | Randomised, double blind, placebo-controlled trial in 3172 HIV-negative, HSV-2–positive participants (1358 women, 1814 men who have sex with men) | Acyclovir, 400 mg twice daily, for 12–18 months | Prevention of HIV acquisition |
Delany et al., 2009 | Randomized, double-blind, placebo-controlled trial in 299 HIV-positive, HSV-2–positive women with CD4 > 250 not on HAART in South Africa | Acyclovir, 400 mg twice daily, for 3 months | Reduction of HIV infectiousness |
Celum et al., 2009 | Randomised, double blind, placebo-controlled trial in 3408 HIV-1 / HSV-2 dually-infected persons within HIV-1 serodiscordant Couples | Acyclovir, 400 mg twice daily, for 12-24 months | Prevention of HIV transmission and disease progression |
Trials of HSV-2 episodic therapy | |||
Paz-Bailey et al., 2009 | Randomised, double blind, placebo-controlled trial in 615 men with genital ulcer disease | Acyclovir 400mg three times a day, for 5 days | Reduction of HIV infectiousness Increased ulcer healing |